Calcium deposits in arterial wall

Calcium deposits in the arterial wall represent a pathological process or biomarker, not a discrete molecular entity that can be directly targeted with drugs. It is a consequence of underlying disease mechanisms rather than a receptor, enzyme, transporter, or other molecular agent that drugs typically bind to or modulate. This phenomenon, clinically known as Coronary Artery Calcification (CAC) when occurring in the coronary system, involves the formation of hydroxyapatite crystals in the extracellular matrix of arterial walls through a complex, regulated biological process resembling bone formation (osteogenesis). Key cellular and molecular players include vascular smooth muscle cells undergoing osteogenic differentiation, macrophages releasing pro-osteogenic cytokines, bone morphogenetic proteins (BMP-2, BMP-4) promoting mineralization, and various matrix proteins (e.g., osteocalcin, osteopontin, alkaline phosphatase). Inhibitory proteins like matrix Gla protein (MGP) and fetuin-A also play a role in preventing calcification. Therefore, it is a pathological outcome rather than a direct therapeutic target.

Other names

Coronary artery calcificationCACArterial calcificationVascular calcificationHydroxyapatite crystals